Boston Scientific shares surge as third quarter results top expectations

MARLBOROUGH, Mass. - On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter results that exceeded analyst expectations, driven by strong performance across its business segments.

The medical device maker’s shares rose 4.08% in pre-market trading after the announcement.

The company posted adjusted earnings per share of $0.75, surpassing the analyst consensus of $0.71. Revenue reached $5.07 billion, beating estimates of $4.97 billion and representing a 20.3% increase from the same period last year. Organic revenue growth was 15.3%, significantly outpacing the company’s guidance range of 12% to 14%.

"We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team," said Mike Mahoney, chairman and chief executive officer of Boston Scientific.

The company’s Cardiovascular segment led growth with a 22.4% revenue increase, while MedSurg grew 16.4%. U.S. sales were particularly robust, jumping 27% compared to the prior year. The stock’s 4% rise reflects investor enthusiasm for these results that exceeded expectations across the board.

Boston Scientific raised its full-year 2025 outlook, now projecting adjusted EPS of $3.02 to $3.04, above the analyst consensus of $2.98. For the fourth quarter, the company expects adjusted EPS between $0.77 and $0.79, also ahead of the $0.76 consensus estimate.

The company continues to expand its product portfolio, recently receiving approval in Japan for expanded labeling of its FARAPULSE Pulsed Field Ablation System and completing an asset acquisition with Elutia, Inc. for antibiotic-eluting envelopes designed to prevent post-operative complications.

Boston Scientific now forecasts full-year 2025 revenue growth of approximately 20% on a reported basis and 15.5% on an organic basis, reflecting continued momentum across its business lines and geographic regions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.